Investigating high-dose Firmonertinib plus Avastin before surgery for EGFR-positive NSCLC
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether combining a targeted therapy (Firmonertinib) with a drug that blocks blood vessel growth (bevacizumab/Avastin) before surgery can shrink tumors in people with a specific type of lung cancer (EGFR mutation-positive, stages II–IIIB). The goal is to increase the chance of successful surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a diagnosis of non-small cell lung cancer (NSCLC) that can be removed with surgery.
- Your cancer must have an EGFR mutation (found through a tissue or blood test).
- Your cancer must be at stage II, IIIA, or IIIB.
- You must be in good physical condition (able to care for yourself and be up and about more than half the day).
- You must not have had any other cancer treatment (chemotherapy, radiation, etc.) before this trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted medicines (befotertinib and bevacizumab) before surgery for people with EGFR-mutant non-small cell lung cancer that cannot be removed right away. The goal is to see if this treatment can shrink the tumor and improve surgery outcomes.
This trial compares a new targeted therapy pill (firmanertinib) to standard chemotherapy in people with advanced non-small cell lung cancer whose tumors have a specific EGFR mutation (PACC or L861Q). If you haven't had treatment for advanced disease and your cancer matches these mutations, this study may offer a more convenient oral option.
This trial tests if Firmonertinib, a targeted pill, can prevent lung cancer from returning after surgery in people with non-small cell lung cancer that has certain uncommon EGFR gene changes. If you have had complete tumor removal and have one of these specific mutations, this study may help you stay cancer-free longer.
This Phase 2 trial studies whether furmonertinib can lower the risk of lung cancer coming back after surgery in certain early-stage lung cancers. You must have EGFR mutations and specific higher-risk features seen on the tumor’s pathology.
This trial tests a targeted pill (Firmonertinib) combined with chemotherapy before surgery for people with early to mid-stage non-small cell lung cancer that has a specific EGFR mutation. The goal is to see if this combination can shrink the tumor and improve outcomes.
This trial tests a targeted cancer drug called firmonertinib for early-stage lung adenocarcinoma that can be surgically removed. The drug targets a specific genetic mutation (EGFR) in the cancer cells and is given before and after surgery to help prevent the cancer from returning.
Hear when a new EGFR Activating Mutation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.